The treatment paradigm of stage II to III triple-negative breast cancer (TNBC) is rapidly evolving, with the recent incorporation of pembrolizumab to neoadjuvant chemotherapy improving disease ...
Norwegian researchers report that cytokines carried on blood-borne extracellular vesicles distinguish ER-positive breast ...
Oncologists are increasingly reaching for the prescription pad before the scalpel, driving a dramatic rise in the use of neoadjuvant therapy for solid tumors, according to new research. The second ...
SurvivorNet on MSN
‘A meaningful step forward’: A wave of FDA approvals bring fresh hope to breast cancer patients
A wave of new FDA approvals is giving breast cancer patients across multiple subtypes — from triple‑negative to HR+/HER2‑ ...
A real-world study of 95 patients in Tokyo confirms that pembrolizumab combined with chemotherapy before and after surgery ...
—Building off of earlier findings, researchers sought to determine rates of neoadjuvant systemic therapy (NST) among U.S. women with cT1–2 N0 M0 HER2-positive breast cancer and identify factors ...
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2+ eBC ...
In this review, we highlight pivotal trials that have informed current practice and ongoing trials that may inform the therapeutic landscape in the coming years. This review summarizes advances in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results